NDATRANSDERMALGEL
Approved
Jan 2009
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
9
Data completeness
5/8 — Partial
GELNIQUE (oxybutynin chloride) by AbbVie is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. First approved in 2009.
Drug data last refreshed 20h ago · AI intelligence enriched 23h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GELNIQUE is a transdermal gel formulation of oxybutynin chloride, an anticholinergic agent approved in 2009 for overactive bladder. It works by relaxing bladder smooth muscle through muscarinic receptor inhibition, reducing involuntary contractions and decreasing urgency and incontinence frequency. The transdermal route provides an alternative to oral dosing with potentially improved tolerability.
$0.816MPart D
PeakStable
4.5 years to LOEProduct is at peak revenue stage with modest Part D spending, indicating mature market with stable demand but limited growth trajectory for commercial expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on GELNIQUE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.